Sangamo Therapeutics Announces Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Patients With Fabry Disease

- Preliminary data showed that isaralgagene civaparvovec, or ST-920, was generally well tolerated - All four patients in the first two dose cohorts exhibited above normal α-Gal A activity, which was maintained for up to one year for the first patient treated - Based on these data, Sangamo has